No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 10 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for SciSparc Ltd. (SPRC) stock was $4.33 as of Oct 6, 2026, 4:00 PM EDT, down 0.69% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -89.7% · 3-year avg -83.0%/yr · 5-year avg -82.6%/yr
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules.
Biotechnology · Tel Aviv, TA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$395000.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SPRC | $250,443 | $4.33 | -0.69% | -89.69% | -82.56% | N/A | N/A |
| 2VRAX | $378,849 | $2.03 | -15.42% | -84.29% | N/A | N/A | vs SPRC |
| 3SLXN | $110,112 | $0.26 | -1.20% | -99.31% | N/A | N/A | vs SPRC |
| 4NIKI | $403,887 | $4.96 | +4.89% | -97.86% | -71.40% | N/A | vs SPRC |
| 5PBM | $95,475 | $5.02 | -1.18% | -73.54% | N/A | N/A | vs SPRC |
| 6PRFX | $70,884 | $0.88 | -0.46% | -87.06% | -74.50% | N/A | vs SPRC |
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.33
High
N/A
